% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • heman_s heman_s Dec 4, 2011 1:44 PM Flag

    Question for drKuvaz pazzingaz

    As you guyz are the veteran, I would like your input. Answers from other posters are also welcome as long as they are not derogatory. Last time when OGXI presented phase 2 data in May 2009 at ASCO annual conference, the SP shot from around 6 to 35. OGX-427 is to be presented Asco GU 2012 for prostate cancer.I know its not a big conference as ASCO annual conf, but do you guyz expect to see any meaningful data n corresponding bump in SP?
    Also the trial is evaluating disease free survival at 12 weeks, will they present the OS data also ? The 10 Q filing only says interim data to be presented at Asco GU 2012 but it doesn't say what parameters will be presented.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.02+0.02(+2.00%)Jul 1 3:57 PMEDT